HAVCR2 and glioblastoma: Nonetheless, the current body of work exploring the key role(s) of TIM-3 expression in patient prognosis and overall TIM-3 biology in the glioblastoma space has provided adequate evidence that therapeutic modulation of TIM-3 is worthy of investigation.